Advancing Gene and Cell Therapies for Patients in Need
Veristat is excited to participate in the 28th Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 13–17 in New Orleans, LA. As the premier event for gene and cell therapy professionals, the ASGCT Annual Meeting is the go-to destination for learning from cutting-edge scientific research, exploring the latest technologies, and connecting with peers across the field.
Your Gene Therapy Development Partner
At Veristat, we specialize in bringing revolutionary therapies to life. With over 30 years of deep expertise in all phases of clinical development, we’ve supported sponsors with game-changing insights. From strategic planning and clinical trial execution to regulatory consulting, our creative approaches have helped them overcome daunting evidentiary and regulatory hurdles to gain swift and successful therapy approval.
Tailored Strategies and Expert Insights
With 35% of our work dedicated to rare and ultra-rare diseases, Veristat brings unmatched experience to cell and gene therapy programs. In the past five years, we’ve:
Supported 100+ clinical trials and consulting projects for cell and gene therapies
Prepared 15+ INDs and CTAs for cell and gene therapies
We ensure rare disease trials qualify for accelerated regulatory pathways, such as Orphan Drug Designation or Priority Review, and support your team through every milestone to bring therapies to patients faster.
Meet with Veristat :
Mandy McCormick – Business Development Manager
Parris Johnson – Senior Business Development Director
Schedule a meeting with our team to discuss how Veristat can accelerate your gene or cell therapy program.
Learn more about the conference